Case report on MET 14 deletion in sarcomatoid non–small-cell lung
cancer detected by next-generat... more Case report on MET 14 deletion in sarcomatoid non–small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor, illustrating the potential of comprehensive genomic profiling to identify mutations that are actionable on clinical trials and the potential activity of crizotinib against MET exon 14 splice site mutations.
Case report on MET 14 deletion in sarcomatoid non–small-cell lung
cancer detected by next-generat... more Case report on MET 14 deletion in sarcomatoid non–small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor, illustrating the potential of comprehensive genomic profiling to identify mutations that are actionable on clinical trials and the potential activity of crizotinib against MET exon 14 splice site mutations.
Uploads
cancer detected by next-generation sequencing and
successfully treated with a MET inhibitor, illustrating the potential of comprehensive genomic profiling to identify mutations that are actionable on clinical trials and the potential activity of crizotinib against
MET exon 14 splice site mutations.
cancer detected by next-generation sequencing and
successfully treated with a MET inhibitor, illustrating the potential of comprehensive genomic profiling to identify mutations that are actionable on clinical trials and the potential activity of crizotinib against
MET exon 14 splice site mutations.